Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD PharmaTimesEarly safety and efficacy signals support move into repeatdose phase 2a trialOphthalmologyRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) PharmaTimes Early safety and efficacy signals support move into repeatdose phase 2a trial Ophthalmology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly, Gilead lead pharma’s M&A boomNext: BMS’ Sotyktu secures EC approval for psoriatic arthritis Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
